Heritage Bio Labs
Research Library
Explore 411 articles about peptides, research compounds and related topics, with links to the original studies.
Find articles
All articles
Showing 157–168 of 411 articles
- Check methods and identity
What a noninvasive liver score measured in the SAMARA trial
Semaglutide is a modified peptide that activates the GLP-1 receptor. The SAMARA study, published in 2026, asked whether noninvasive tests could detect a change in adults with suspected at-risk metabolic dysfunction-associated steatohepatitis, or MASH, who were assigned to semaglutide or placebo.
GLP-1 SEMA2 sources (2026)
- Explore study findings
What a 2026 analysis found across sleep apnea subgroups
Tirzepatide is a modified peptide that activates the GIP and GLP-1 receptors. “GLP-2 TIRZ” is the catalog label. Tirzepatide’s tested targets are GIP and GLP-1, distinct from the GLP-2 receptor. A 2026 analysis asked how sleep apnea outcomes varied with participants’ starting characteristics.
GLP-2 TIRZ3 sources (2022–2026)
- Interpret the evidence
Why the heart outcomes trial used an active comparator
Tirzepatide activates GIP and GLP-1 receptors. The catalog wording “GLP-2 TIRZ” refers to tirzepatide and does not identify a GLP-2 target.
GLP-2 TIRZ3 sources (2022–2026)
- Check methods and identity
What an antibody add-on study measured besides weight
Tirzepatide is a peptide that activates GIP and GLP-1 receptors. The “GLP-2” wording in the catalog label does not correspond to a receptor target.
GLP-2 TIRZ2 sources (2022, 2026)
- Check methods and identity
How SURMOUNT-MAINTAIN tested weight maintenance
Tirzepatide activates GIP and GLP-1 receptors. In “GLP-2 TIRZ,” the GLP-2 wording is a catalog identifier. The SURMOUNT-MAINTAIN trial examined what happened to body weight after adults had already taken tirzepatide during an initial weight-loss phase.
GLP-2 TIRZ2 sources (2022, 2026)
- Explore study findings
What a head-to-head trial taught researchers about glucose categories
Tirzepatide is a peptide that activates GIP and GLP-1 receptors. It appears under “GLP-2 TIRZ” in the catalog, a name distinct from its receptor targets.
GLP-2 TIRZ3 sources (2022–2026)
- Understand the science
Which two receptors recognize tirzepatide?
Tirzepatide is designed to activate the receptors for glucose-dependent insulinotropic polypeptide, called GIP, and glucagon-like peptide-1, called GLP-1. The “GLP-2” part of the catalog label refers to the label alone.
GLP-2 TIRZ1 source (2022)
- Interpret the evidence
What a 2026 blood study can tell us about glutathione exposure
Glutathione is a naturally occurring three-amino-acid peptide that can shift between reduced and oxidized forms. A 2026 clinical study compared several glutathione products and asked how levels of the peptide and related compounds changed in blood.
Glutathione2 sources (2014, 2026)
- Check methods and identity
What the October 2026 recall tells us about product quality
Glutathione is a naturally occurring peptide made of three amino acids that participates in those protective reactions. A recall posted by the FDA in October 2026 concerned a different question, whether certain compounded glutathione products met a safety standard for bacterial endotoxins.
Glutathione2 sources (2019, 2026)
- Check methods and identity
Why brain glutathione and blood flow were measured separately
Glutathione is a three-amino-acid peptide produced by cells, including cells in the brain. In October 2026, researchers reported a human study in which they measured brain glutathione and blood flow during a dietary comparison.
Glutathione1 source (2026)
- Understand the science
How baseline glutathione mattered in a human muscle study
Glutathione is a naturally produced three-amino-acid peptide involved in that balance. A 2026 human study examined whether baseline glutathione status mattered for the response of muscle to an experimental injury.
Glutathione1 source (2026)
- Check methods and identity
Why a glutathione acne trial measured both blood markers and skin changes
Glutathione is a naturally occurring three-amino-acid peptide involved in those reactions. A small randomized acne trial published in September 2025, just before the recent research window, examined both blood markers and changes in acne severity.
Glutathione1 source (2025)
Browse by product
- A4 Amyloid Beta6 articles
- ACE-0316 articles
- ACE-0836 articles
- Adipotide6 articles
- AICAR6 articles
- AOD-96046 articles
- ARA-2906 articles
- BPC-1576 articles
- BPC-157 / TB-5006 articles
- Cagrilintide7 articles
- CJC-1295 (No DAC) / GHRP-26 articles
- CJC-1295 (No DAC) / GHRP-66 articles
- CJC-1295 (No DAC) / Ipamorelin6 articles
- CJC-1295 No DAC6 articles
- CJC-1295 With DAC6 articles
- DSIP6 articles
- Epitalon6 articles
- Follistatin 3156 articles
- Follistatin 3446 articles
- Fragment 176-1916 articles
- GHK-Cu6 articles
- GHRP-26 articles
- GHRP-66 articles
- GLOW 2 Blend6 articles
- GLOW Blend6 articles
- GLP-1 SEMA6 articles
- GLP-2 TIRZ6 articles
- Glutathione6 articles
- HCG6 articles
- Hexarelin6 articles
- Human Relaxin-26 articles
- IGF-1 DES 1,36 articles
- IGF-1 Human6 articles
- IGF-2 LR36 articles
- IGF-DES 1,36 articles
- IGF-LR36 articles
- Ipamorelin6 articles
- Kisspeptin-106 articles
- KLOW Blend6 articles
- KPV6 articles
- Lipopeptide6 articles
- Liraglutide6 articles
- Melanotan II5 articles
- MGF6 articles
- MOTS-C6 articles
- MSC Exosomes6 articles
- Myostatin6 articles
- Myostatin HMP (GDF8)6 articles
- Oxytocin7 articles
- PEG-MGF6 articles
- Pinealon6 articles
- PT-1416 articles
- RETA / IGF-1 LR36 articles
- RETA GLP-36 articles
- Selank6 articles
- SEMA / IGF-1 LR36 articles
- Semax6 articles
- Sermorelin6 articles
- SLU-PP-3326 articles
- SNAP-86 articles
- Survodutide7 articles
- TB-5006 articles
- Tesamorelin6 articles
- Thymosin Alpha-16 articles
- TIRZ / IGF-1 LR36 articles
- TIRZ GLP-26 articles
- Trevogrumab6 articles
- Triptorelin GnRH6 articles
